The life sciences industry is entering one of its most dynamic periods of innovation and expansion. Breakthroughs in biologics, advanced therapies, and drug-device combination products are reshaping the way medicines are developed, manufactured, and delivered to patients.
With these scientific advances comes a new level of complexity. Companies must navigate increasingly sophisticated technologies, evolving regulatory expectations, and the operational demands of scaling manufacturing from early development through commercial production.
Across the industry, sponsors are looking for partners who can help bridge those gaps. The need for integrated expertise across development, quality, manufacturing, and regulatory strategy has never been greater.
Against this backdrop, Kymanox has appointed Evan Edwards as Chief Executive Officer, positioning the company to expand its capabilities and continue supporting pharmaceutical, biotechnology, and medical device innovators through the full product lifecycle.
Founder Stephen M. Perry will transition to Executive Chairman of the Board, where he will remain actively engaged in guiding the company’s long-term strategy.
“Evan is the ideal leader to shepherd Kymanox into its next era of enterprise growth,” said Perry. “As Executive Chairman, I will remain actively engaged in supporting Evan and shaping our strategic direction for the years ahead.” The leadership transition is part of a well-planned, forward-looking strategy to strengthen the position of Kymanox in the industry.
Kymanox also announced the appointment of Nicholas Ciccarelli as Chief Operating Officer, strengthening the leadership team as the firm prepares for its next phase of growth.
An Industry at an Inflection Point
Innovation across the life sciences sector is accelerating. Cell and gene therapies are moving rapidly through clinical pipelines. Biologics continue to dominate new drug approvals. Combination products are becoming more sophisticated as companies integrate drug, device, and digital technologies into single therapeutic platforms.
These advances are transforming not only how therapies are designed but also how they are developed, manufactured, validated, and brought to market.
For many companies, the challenge is no longer just discovery. It is execution.
Scaling a therapy from early development to commercial manufacturing requires expertise across multiple disciplines, including facility readiness, process engineering, validation, regulatory compliance, and quality systems. As pipelines become more complex, companies increasingly rely on partners who can provide integrated support across these stages rather than isolated services.
This shift is driving significant demand for firms that can combine deep technical expertise with operational execution.
It is exactly the environment Kymanox was built to support.
About the New CEO: Builder, Inventor, Operator
Evan Edwards brings a unique perspective to leading Kymanox at this moment in the industry.
Before joining the company, Edwards co-founded Kaleo, a pharmaceutical company focused on developing innovative drug-device combination products. His experience building a company from concept to commercial product gave him first-hand insight into the challenges life sciences companies face as they navigate development, regulatory pathways, and manufacturing scale-up.
Edwards is named on more than 200 patents related to pharmaceutical and medical device technologies, reflecting a career centered on innovation and problem solving. Based in Charlottesville, Virginia, Edwards brings hands-on operational fluency that Kymanox’s clients will require of their trusted partners.
Since joining Kymanox, he has played a key role in shaping the company’s strategic direction and expanding its capabilities. Most recently serving as President, Edwards has overseen day-to-day operations while helping guide the firm’s growth across multiple service areas.
“We are optimistic about the future of our company and the life sciences industry,” said Edwards. “Our focus remains on scaling our capabilities, deepening client partnerships, and delivering integrated solutions. We are committed to supporting sponsors as they navigate increasingly complex development and manufacturing challenges.”
Kymanox: A Global Leader
Kymanox was founded by Stephen M. Perry in 2004 with a clear mission: help life sciences companies navigate the complex path from early development through commercialization to get products from the bench to the patient.
Over the past two decades, that mission has evolved alongside the industry itself. In 2021, Kymanox raised private-equity growth capital which led to multiple targeted acquisitions that expanded Kymanox’s capabilities and geographic reach.
One of those strategic investments was the 2021 acquisition of Neuma, a Philadelphia-area engineering services provider co-founded by Nicholas Ciccarelli, PE. The acquisition significantly strengthened Kymanox’s expertise in drug-device combination products and engineering services.
Ciccarelli’s appointment as Chief Operating Officer reflects the company’s continued focus on operational excellence as it scales.
The leadership team now combines entrepreneurial experience, operational leadership, and deep technical expertise across the life sciences sector.
Today, Kymanox provides integrated services spanning:
- Design, Development, and Testing
- Quality and Compliance
- Biologics and Advanced Therapies
- Combination Products
- Facilities and Manufacturing Services
The company has supported organizations ranging from emerging biotechnology startups to global pharmaceutical manufacturers, helping them solve challenges across the full product lifecycle.
As scientific innovation accelerates, the company is continuing to expand its expertise in areas where demand is growing most rapidly, including advanced therapies, complex combination products, and modern pharmaceutical manufacturing.
The Next Chapter: Scale, Integration, and Client Success
The next decade will likely bring even greater change to the life sciences landscape.
Emerging therapies are becoming more personalized. Manufacturing technologies are evolving. Regulatory expectations continue to adapt to new scientific frontiers.
For companies developing the next generation of therapies, success will increasingly depend on their ability to move seamlessly from innovation to execution.
Kymanox is positioning itself to meet that challenge. In his own words, Edwards is focused on three things: scaling capabilities, deepening client partnerships, and delivering integrated solutions.
Under Edwards’ leadership, the company plans to continue expanding its integrated services and developing new capabilities aligned with emerging industry needs, ensuring clients have the expertise required to bring increasingly complex therapies to patients.
For Kymanox, the opportunity ahead is not just growth. It is helping life sciences innovators translate scientific breakthroughs into real-world therapies that improve and extend lives.
And in an industry driven by innovation, that mission has never been more important.
For a company whose reason for being is that “patients deserve better”, the pressure to deliver is as clear as it gets. Edwards knows it and is the right person to see it through.
Read more here.